Bladder Cancer
Dec 24, 2024, 14:29
Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma
Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:
“Advanced urothelial carcinoma patients with TSC1 mutations show higher response rates to EV monotherapy (87% vs. 51%), while presence of CDKN2A/B is neg associated with PFS (4.6 vs. 6 ) mo. (Nectin4 is not available).”
Authors: Tanya Jindal et al.
advanced urothelial carcinoma
Ajjai Alva
Ali Raza Khaki.
Amanda Nizam
Arnab Basu
Cameron Pywell
cancer
Charles Nguyen
Christopher Hoimes
Cindy Jiang
Deepak Kilari
Dimitra Bakaloudi
Dory Freeman
Emily Lemke
Hamid Emamekhoo
Joaquim Bellmunt
Laura Bukavina
Matthew Davidsohn
Matthew I. Milowsky
Matthew T Campbell
Mehmet A Bilen
Michael Glover
Nancy B. Davis
Omar Alhalabi
OncoDaily
Oncology
Pedro C Barata
Petros Grivas
Rafee Talukder
Rohit Bose
Sean Evans
Shilpa Gupta
Sumit A. Shah
Tanya Jindal
Vadim S Koshkin
Woogwang Sim
Yousef Zakharia
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38